{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:56:27Z","timestamp":1790704587974,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.tcm.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T04:48:09Z","timestamp":1478321289000},"page":"216-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Gene therapy for heart failure"],"prefix":"10.1016","volume":"27","author":[{"given":"Barry","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2016.11.001_bib1","first-page":"e6","article-title":"Heart disease and stroke statistics--2013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/eurheartj\/ehv220","article-title":"Cardiovascular diseases in populations: secular trends and contemporary challenges-geoffrey rose lecture European Society of Cardiology Meeting 2014","volume":"36","author":"Roger","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.tcm.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2011.148","article-title":"Gene therapy targets in heart failure: the path to translation","volume":"90","author":"Raake","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/CIRCRESAHA.113.300269","article-title":"Heart failure gene therapy: the path to clinical practice","volume":"113","author":"Pleger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib11","first-page":"285","article-title":"Advances in gene therapy for heart failure","volume":"19","author":"Fish","year":"2015","journal-title":"Discov Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HCO.0000000000000159","article-title":"Adeno-associated virus-mediated gene therapy in cardiovascular disease","volume":"30","author":"Hammoudi","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib15","first-page":"67","article-title":"State-of-the-art human gene therapy: part I. Gene delivery technologies","volume":"18","author":"Wang","year":"2014","journal-title":"Discov Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib16","first-page":"151","article-title":"State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications","volume":"18","author":"Wang","year":"2014","journal-title":"Discov Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib18","doi-asserted-by":"crossref","first-page":"e35875","DOI":"10.1371\/journal.pone.0035875","article-title":"Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling","volume":"7","author":"Miyazaki","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1586\/14779072.2014.967683","article-title":"Methods to improve cardiac gene therapy expression","volume":"12","author":"Scimia","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/gt.2012.3","article-title":"Cardiac gene therapy in large animals: bridge from bench to bedside","volume":"19","author":"Ishikawa","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jgm.1609","article-title":"Gene delivery methods in cardiac gene therapy","volume":"13","author":"Ishikawa","year":"2011","journal-title":"J Gene Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12265-013-9479-7","article-title":"Percutaneous approaches for efficient cardiac gene delivery","volume":"6","author":"Ishikawa","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2011.22","article-title":"Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer","volume":"19","author":"Pulicherla","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gt.3303035","article-title":"Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors","volume":"15","author":"Raake","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.gt.3301079","article-title":"Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins","volume":"7","author":"Boekstegers","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/hgtb.2012.129","article-title":"Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression","volume":"24","author":"Chen","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.tcm.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/mt.2011.268","article-title":"Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts","volume":"20","author":"Karakikes","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/gt.2015.109","article-title":"Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure","volume":"23","author":"Greenberg","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/01.RES.61.1.70","article-title":"Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure","volume":"61","author":"Gwathmey","year":"1987","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00424-014-1469-3","article-title":"Ca handling during excitation-contraction coupling in heart failure","volume":"466","author":"Zima","year":"2014","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.tcm.2016.11.001_bib31","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","article-title":"Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure","volume":"51","author":"Kawase","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.CIR.92.4.778","article-title":"Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy","volume":"92","author":"Meyer","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib33","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1161\/01.CIR.100.23.2308","article-title":"Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a","volume":"100","author":"del Monte","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCEP.110.961615","article-title":"SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure","volume":"4","author":"Lyon","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.tcm.2016.11.001_bib36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchf.2013.09.008","article-title":"Design of a phase 2b trial of intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)","volume":"2","author":"Greenberg","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.tcm.2016.11.001_bib39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2016.11.001_bib40","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tcm.2016.11.001_bib41","first-page":"I26","article-title":"Mechanisms of abnormal transmembrane signaling of the beta-adrenergic receptor in congestive heart failure","volume":"82","author":"Horn","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib42","doi-asserted-by":"crossref","first-page":"13C","DOI":"10.1016\/0002-9149(91)90068-V","article-title":"Adrenergic receptor responsiveness and congestive heart failure","volume":"67","author":"Stiles","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0008-6363(95)00152-2","article-title":"Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure","volume":"30","author":"Brodde","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0008-6363(02)00539-4","article-title":"Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function","volume":"56","author":"Gao","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2016.11.001_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00395-003-0429-4","article-title":"Cardiac-directed expression of adenylyl cyclase and heart rate regulation","volume":"98","author":"Roth","year":"2003","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: a Randomized Clinical Trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2016.11.001_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(03)14232-8","article-title":"Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy","volume":"362","author":"Askari","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2016.11.001_bib48","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1161\/01.CIR.0000055313.77510.22","article-title":"Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization","volume":"107","author":"Yamaguchi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2016.11.001_bib49","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/gt.2011.18","article-title":"Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure","volume":"18","author":"Sundararaman","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.tcm.2016.11.001_bib50","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173816301712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173816301712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T18:25:16Z","timestamp":1560882316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173816301712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1050173816301712"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2016.11.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for heart failure","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}